RECURSION PHARMACEUTICALS, INC. Goodwill, Foreign Currency Translation Gain (Loss)
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Goodwill, Foreign Currency Translation Gain (Loss) of $1.81 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:GoodwillForeignCurrencyTranslationGainLoss · last filed 2026-08-05
- RECURSION PHARMACEUTICALS, INC. goodwill, foreign currency translation gain (loss) for the quarter ending 2026-06-30 was -$180.00K.
- RECURSION PHARMACEUTICALS, INC. goodwill, foreign currency translation gain (loss) for the quarter ending 2026-03-31 was $1.99M.
- RECURSION PHARMACEUTICALS, INC. goodwill, foreign currency translation gain (loss) for the quarter ending 2025-12-31 was -$116.00K.
- RECURSION PHARMACEUTICALS, INC. goodwill, foreign currency translation gain (loss) for the quarter ending 2025-09-30 was $2.23M.
- RECURSION PHARMACEUTICALS, INC. goodwill, foreign currency translation gain (loss) for fiscal 2025 was -$7.34M, a 899.35% decline from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. goodwill, foreign currency translation gain (loss) for fiscal 2024 was $918.00K.
| Period end | Goodwill, Foreign Currency Translation Gain (Loss) 3 month | Goodwill, Foreign Currency Translation Gain (Loss) 6 month | Goodwill, Foreign Currency Translation Gain (Loss) 9 month | Goodwill, Foreign Currency Translation Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$180.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.81M 10-Q · filed 2026-08-05 | $1.69M derived: sum of 3 quarters · filed 2026-08-05 | $3.92M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $1.99M 10-Q · filed 2026-05-06 | $1.87M derived: sum of 2 quarters · filed 2026-05-06 | $4.10M derived: sum of 3 quarters · filed 2026-05-06 | -$2.06M derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-12-31 | -$116.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $2.11M derived: sum of 2 quarters · filed 2026-02-25 | -$4.05M derived: sum of 3 quarters · filed 2026-02-25 | -$7.34M 10-K · filed 2026-02-25 |
| 2025-09-30 | $2.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$3.93M derived: sum of 2 quarters · filed 2025-11-05 | -$7.22M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | -$6.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$9.45M 10-Q · filed 2025-08-05 | ||
| 2025-03-31 | -$3.29M 10-Q · filed 2025-05-05 | |||
| 2024-12-31 | $918.00K 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |